For Boston Scientific (NYSE:BSX) and its ongoing legal woes over the blockbuster acquisition of Guidant Corp. , you win some and you lose some.
Legal News
ArthroCare shares flat on DoJ overhang despite swings to Q4, 2012 black
Investors stayed on the sidelines last week on shares of ArthroCare (NSDQ:ARTC), despite its return to black ink for both the 4th quarter and full year, as they awaited more information on pending U.S. Justice Dept. investigations.
UPDATE: OrbusNeich claims European stent patent win over Boston Scientific
UPDATED Feb. 13, 2012 with comment from Boston Scientific.
OrbusNeich claimed a win over Boston Scientific (NYSE:BSX) in a European patent battle over stent technology.
WebMD, MMRGlobal battle over personal health record patents
Online healthcare management services provider MMRGlobal sued rival digital health company WebMD over alleged patent infringement.
MMRGlobal claims that WebMD has built relatively new features into its online personal wellness tracking system that infringe on patents covering consumer-controlled personal health records.
Healthcare fraud recovery pays for itself – and then some | MassDevice.com On Call
MASSDEVICE ON CALL — For every $1 regulators spend fighting healthcare fraud and abuse during the last 3 years they recovered a record $7.90, the highest 3-year average return to date.
Healthcare fraud prevention programs collected $4.2 billion in fiscal year 2012, up from about $4.1 billion in 2011. Over the last 4 years the policing initiatives have recovered $14.9 billion, according to an official report.
Supreme Court denies Retractable Technologies in patent war with BD
Cancer: Sarif Biomedical sues Accuray over CyberKnife
Sarif Biomedical accused Accuray (NSDQ:ARAY) of infringing 1 of its patents with the CyberKnife radiosurgery device for cancer, which uses targeted radiation blasts to destroy tumor cells.
Tool, Texas-based Sarif’s patent covers ""Computer-Assisted Microsurgery Methods and Equipment." The medical device company alleges that Accuray’s device trespasses on that intellectual property, according to the lawsuit.
Breast cancer: Judge stays C.R. Bard suit against Hologic over Mammosite device
Lawsuit: Stryker should cover Fla. patients’ medical monitoring over recalled Rejuvenate hip implant
Abiomed CEO Minogue on DoJ probe, FDA call
Cardiologists aren’t paying much attention to the noise around Abiomed (NSDQ:ABMD) and its flagship medical device, the Impella heart pump, at least according to chairman, president & CEO Michael Minogue.
That noise centered around a pair of events during the 4th quarter: news of a U.S. Justice Dept. probe into its marketing of the Impella pump and an FDA decision to require the device to undergo a more rigorous approval process.
MassDevice.com +3 | The top 3 med-tech stories for Feb. 6, 2013
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.